Phase 3 Readout
ABBV: Phase 3 Topline: A Multicenter, Double-masked, Randomized Study to Compare the Efficacy and Safety of the ABBV-444 Te
August 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- August 1, 2026
- Company
- AbbVie Inc. (ABBV)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Multicenter, Double-masked, Randomized Study to Compare the Efficacy and Safety of the ABBV-444 Te
- Company
- AbbVie Inc. (ABBV)
- Indication
- Dry Eye Disease
Other upcoming events for ABBV
Phase 2 StartPhase 2 Start: A Phase 2, Open-Label, Master Protocol Study to Evaluate Safety and Efficacy of Treatment Combinatio
Phase 2 StartPhase 2 Start: A Phase 2 Open-Label Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotu
Phase 3 ReadoutPhase 3 Topline: Randomized, Double-blind, Placebo-Controlled, Multiple-Attack Study With an Open-Label Extension to
Phase 3 ReadoutPhase 3 Topline: A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy an